HOXB13 induces growth suppression of prostate cancer cells as a repressor of hormone-activated androgen receptor signaling

Cancer Research

Volumn 64, Issue 24, 2004, Pages 9185-9192

  Jung, Chaeyong ^a,b   Kim, Ran Sook ^a   Zhang, Hong Ji ^a   Lee, Sang Jin ^a   Jeng, Meei Huey ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; HOMEODOMAIN PROTEIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN HOXB13; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

ANDROGENS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; COLON; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RECTUM; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 10844266655     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-1330     Document Type: Article

References (44)

1. Heinlein CA, Chang C. Androgen receptor (AR) coregulators: an overview. Endocr Rev 2002;23:175-200.
2. Onate SA, Boonyaratanakornkit V, Spencer TE, et al. The steroid receptor coactivator-1 contains multiple receptor interacting and activation domains that cooperatively enhance the activation function 1 (AF1) and AF2 domains of steroid receptors J Biol Chem 1998;273:12101-8.
3. Ma H, Hong H, Huang SM, et al. Multiple signal input and output domains of the 160-kilodalton nuclear receptor coactivator proteins. Mol Cell Biol 1999;19:6164-73.
4. Webb P, Nguyen P, Shinsako J, et al. Estrogen receptor activation function 1 works by binding p160 coactivator proteins. Mol Endocrinol 1998;12:1605-18.
5. Cheng S, Brzostek S, Lee SR, Hollenberg AN, Balk SP. Inhibition of the dihydrotestosterone-activated androgen receptor by nuclear receptor corepressor. Mol Endocrinol 2002;16:1492-501.
6. Cillo C, Cantile M, Faiella A, Boncinelli E. Homeobox genes in normal and malignant cells. J Cell Physiol 2001;188:161-9.
7. Takahashi Y, Hamada J, Murakawa K, et al. Expression profiles of 39 HOX genes in normal human adult organs and anaplastic thyroid cancer cell lines by quantitative real-time RT-PCR system. Exp Cell Res 2004;293:144-53.
8. Podlasek CA, Clemens JQ, Bushman W. Hoxa-13 gene mutation results in abnormal seminal vesicle and prostate development. J Urol 1999;161:1655-61.
9. Prins GS, Birch L, Habermann H, et al. Influence of neonatal estrogens on rat prostate development. Reprod Fertil Dev 2001;13:241-52.
10. Podlasek CA, Duboule D, Bushman W. Male accessory sex organ morphogenesis is altered by loss of function of Hoxd-13. Dev Dyn 1997;208:454-65.
11. Warot X, Fromental-Ramain C, Fraulob V, Chambon P, Dolle P. Gene dosage-dependent effects of the Hoxa-13 and Hoxd-13 mutations on morphogenesis of the terminal parts of the digestive and urogenital tracts. Development 1997;124:4781-91.
12. Zeltser L, Desplan C, Heintz N. Hoxb-13: a new Hox gene in a distant region of the HOXB cluster maintains colinearity. Development 1996;122:2475-84.
13. Sreenath T, Orosz A, Fujita K, Bieberich CJ. Androgen-independent expression of hoxb-13 in the mouse prostate. Prostate 1999;41:203-7.
14. Economides KD, Zeltser L, Capecchi MR. Hoxb13 mutations cause overgrowth of caudal spinal cord and tail vertebrae. Dev Biol 2003;256:317-30.
15. Economides KD, Capecchi MR. Hoxb13 is required for normal differentiation and secretory function of the ventral prostate. Development 2003;130:2061-9.
16. Jung C, Kim RS, Lee SJ, Wang C, Jeng MH. HOXB13 homeodomain protein suppresses the growth of prostate cancer cells by the negative regulation of T-cell factor 4. Cancer Res 2004;64:3046-51.
17. Lee SJ, Kim HS, Yu R, et al. Novel prostate-specific promoter derived from PSA and PSMA enhancers. Mol Ther 2002;6:415-21.
18. Cleutjens KB, van der Korput HA, van Eekelen CC, et al. An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter. Mol Endocrinol 1997;11:148-61.
19. Wu TT, Sikes RA, Cui Q, et al. Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines. Int J Cancer 1998;77:887-94.
20. Jung C, Ou YC, Yeung F, Frierson HF Jr, Kao C. Osteocalcin is incompletely spliced in non-osseous tissues. Gene 2001;271:143-50.
21. Lee SJ, Lee K, Yang X, et al. NFATc1 with AP-3 site binding specificity mediates gene expression of prostate-specific-membrane-antigen. J Mol Biol 2003;330:749-60.
22. Navone NM, Olive M, Ozen M, et al. Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin Cancer Res 1997;3:2493-500.
23. Navone NM, Rodriquez-Vargas MC, Benedict WF, et al. TabBO: a model reflecting common molecular features of androgen-independent prostate cancer. Clin Cancer Res 2000;6:1190-7.
24. Zhao XY, Peehl DM, Navone NM, Feldman D. 1 alpha,25-Dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms. Endocrinology 2000;141:2548-56.
25. Jongsma J, Oomen MH, Noordzij MA, et al. Different profiles of neuroendocrine cell differentiation evolve in the PC-310 human prostate cancer model during long-term androgen deprivation. Prostate 2002;50:203-15.
26. van Weerden WM, de Ridder CM, Verdaasdonk CL, et al. Development of seven new human prostate tumor xenograft models and their histopathological characterization. Am J Pathol 1996;149:1055-62.
27. Kokontis J, Takakura K, Hay N, Liao S. Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res 1994;54:1566-73.
28. Heisler LE, Evangelou A, Lew AM, Trachtenberg J, Elsholtz HP, Brown TJ. Androgen-dependent cell cycle arrest and apoptotic death in PC-3 prostatic cell cultures expressing a full-length human androgen receptor. Mol Cell Endocrinol 1997;126:59-73.
29. Brass AL, Barnard J, Patai BL, Salvi D, Rukstalis DB. Androgen up-regulates epidermal growth factor receptor expression and binding affinity in PC3 cell lines expressing the human androgen receptor. Cancer Res 1995;55:3197-3203.
30. Jackson TA, Richer JK, Bain DL, Takimoto GS, Tung L, Horwitz KB. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. Mol Endocrinol 1997;11:693-705.
31. Wagner BL, Norris JD, Knotts TA, Weigel NL, McDonnell DP. The nuclear corepressors NCoR and SMRT are key regulators of both ligand- and 8-bromo-cyclic AMP-dependent transcriptional activity of the human progesterone receptor. Mol Cell Biol 1998;18:1369-78.
32. Petre CE, Wetherill YB, Danielsen M, Knudsen KE. Cyclin D1: mechanism and consequence of androgen receptor co-repressor activity. J Biol Chem 2002;277:2207-15.
33. Zhang Y, Yang Y, Yeh S, Chang C. ARA67/PAT1 functions as a repressor to suppress androgen receptor transactivation. Mol Cell Biol 2004;24:1044-57.
34. Yu X, Li P, Roeder RG, Wang Z. Inhibition of androgen receptor-mediated transcription by amino-terminal enhancer of split. Mol Cell Biol 2001;21:4614-25.
35. Levine M, Hoey T. Homeobox proteins as sequence-specific transcription factors. Cell 1988;55:537-40.
36. Shen WF, Chang CP, Rozenfeld S, et al. Hox homeodomain proteins exhibit selective complex stabilities with Pbx and DNA. Nucleic Acids Res 1996;24:898-906.
37. Mann RS, Chan SK. Extra specificity from extradenticle; the partnership between HOX and PBX/EXD homeodomain proteins. Trends Genet 1996;12:258-62.
38. Raman V, Tamori A, Vali M, Zeller K, Korz D, Sukumar S. HOXA5 regulates expression of the progesterone receptor. J Biol Chem 2000;275:26551-5.
39. Shen WF, Krishnan K, Lawrence HJ, Largman C. The HOX homeodomain proteins block CBP histone acetyltransferase activity. Mol Cell Biol 2001;21:7509-22.
40. Amir AL, Barua M, McKnight NC, Cheng S, Yuan X, Balk SP. A direct beta-catenin-independent interaction between androgen receptor and T cell factor 4. J Biol Chem 2003;278:30828-34.
41. Chesire DR, Isaacs WB. Ligand-dependent inhibition of beta-catenin/TCF signaling by androgen receptor. T cell factor. Oncogene 2002;21:8453-69.
42. Denmeade SR, Lin XS, Isaacs JT. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 1996;28:251-65.
43. Davies P, Eaton CL. Regulation of prostate growth. J Endocrinol 1991;131:5-17.
44. Song LN, Herrell R, Byers S, Shah S, Wilson EM, Gelmann EP. Beta-catenin binds to the activation function 2 region of the androgen receptor and modulates the effects of the N-terminal domain and TIF2 on ligand-dependent transcription. Mol Cell Biol 2003;23:1674-87.